查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1484115

生物相似藥/後續生物製劑市場：2024-2034

Biosimilars and Follow-On Biologics Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 391 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球生物相似藥/後續生物製劑市場規模將以 14.8% 的複合年增長率成長。

對治療慢性疾病的藥物的需求不斷增加：

糖尿病、類風濕性關節炎和各種癌症等慢性疾病正在增加，增加了對有效長期治療的需求。這種激增是由多種因素推動的，包括人口老化、與生活方式相關的疾病增加以及能夠實現早期檢測和長期治療的醫學進步。

隨著人們對疾病機制的瞭解不斷加深，生物製劑處於醫療創新的最前沿，為患有以前無法治療的疾病的患者帶來了希望。此外，不斷提高的醫療保健意識和不斷發展的提倡積極管理慢性病的政策也進一步促進了對生物製劑的需求不斷增長。

有利於生物相似藥審批的監管政策：

知道全球監管機構確保生物相似藥符合嚴格的品質、安全性和功效標準並建立清晰透明的生物相似藥審批途徑的重要性。

有利的監管政策的關鍵要素之一是建立針對生物相似藥獨特特性的具體指南和框架。與相對容易複製的小分子藥物不同，生物製劑是在活細胞內產生的大而複雜的分子，這使得它們的開發和表徵更加困難。監管途徑允許生物相似藥製造商依賴參考生物製劑的現有臨床數據，這加快了審批過程，同時提供了相似性和安全性的有力證據，需要比較分析測試和臨床試驗。透過設定明確的期望和要求，這些指南使製造商能夠更有效率地駕馭監管流程，加速生物相似藥的開發和批准。

該報告調查了全球生物相似藥/後續生物製品市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測，以及依各個細分市場、地區和主要國家進行的細分。

目錄

第一章 報告概述

第二章執行摘要

第 3 章市場概況

  • 主要發現
  • 市場動態
    • 市場驅動力
    • 市場限制因素
    • 市場機會
  • COVID-19 影響分析
  • 生物相似藥收入：依地區劃分
  • 生物相似藥最新審批時間表
  • 最新生物相似藥交易
  • 核准的生物相似藥清單
  • 最近推出的生物相似藥列表
  • 波特五力分析
  • PEST分析

第 4 章 生物相似藥/後續生物製劑市場分析：依產品類型

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 重組非糖基化蛋白
    • 依產品類型
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
    • 人類生長激素
    • 粒細胞集落刺激因子（非格司亭）
    • 胰島素
    • 干擾素
  • 重組糖化蛋白
    • 依產品類型
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
    • 促紅細胞生成素
    • 單克隆抗體
    • 促卵泡素
    • 低分子肝素

第五章生物相似藥/後續生物製品市場分析：依應用

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 血
    • 依類型
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
    • 嗜中性白血球減少症
    • 貧血
    • 其他
  • 腫瘤
    • 依類型
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
    • 肺癌
    • 腦腫瘤
    • 乳癌
    • 子宮頸癌
    • 大腸直腸癌
    • 白血病
    • 其他
  • 自身免疫性疾病
    • 依類型
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
    • 關節炎
    • 炎症性腸病
    • 銀屑病
    • 其他
  • 生長激素缺乏
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
  • 糖尿病
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區
  • 其他
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第六章 生物相似藥/後續生物製劑市場分析：依技術分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 重組 DNA (rDNA) 技術
  • 單株抗體（MAb）技術
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第七章 生物相似藥/後續生物製劑市場分析：依製造商分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 合約研究和合約製造服務
  • 內部
    • 市場規模趨勢與預測：依地區
    • 市佔率：依地區

第八章 生物相似藥/後續生物製劑市場分析：依地區

  • 主要發現
  • 市場規模趨勢和預測

第九章北美生物相似藥/後續生物製劑市場分析

第10章歐洲生物相似藥/後續生物製劑市場分析

第十一章亞太地區生物相似藥/後續生物製劑市場分析

第十二章拉丁美洲生物相似藥/後續生物製劑市場分析

第十三章中東和非洲生物相似藥/後續生物製劑市場分析

第十四章公司簡介

  • 競爭格局
  • 戰略視角
  • Amgen Inc.
  • Apotex (Apobiologix)
  • Biocad
  • Biocon Biologics Ltd.
  • Bio-Thera Solutions
  • Coherus Biosciences
  • Dr. Reddy's Laboratories
  • Fresenius Kabi (Fresenius SE &Co. KGaA)
  • Intas Pharma
  • Pfizer
  • Reliance Life Sciences
  • Samsung Bioepis (Samsung Biologics)
  • Sandoz Group AG
  • Teva Pharmaceuticals Industries Ltd.

第十五章 一般性意見/建議

  • Visiongain 的一般討論
  • 對參與企業的建議
Product Code: PHA1332

The global Biosimilars and Follow-on Biologics market is projected to grow at a CAGR of 14.8% by 2034

The Biosimilars and Follow-on Biologics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand of Drugs For Treating Chronic Conditions

The increasing demand for drugs stems from their remarkable efficacy in treating a wide array of chronic and complex diseases, ranging from cancer to autoimmune disorders and beyond. Chronic conditions such as diabetes, rheumatoid arthritis, and various forms of cancer are becoming increasingly prevalent, driving up the need for effective long-term treatments. This surge is propelled by various factors, including the aging population, the prevalence of lifestyle-related ailments, and advancements in medical science enabling earlier detection and prolonged treatment.

As our understanding of disease mechanisms deepens, biologics continue to be at the forefront of medical innovation, offering hope for patients with previously untreatable conditions. Additionally, heightened awareness and evolving healthcare policies advocating proactive management of chronic illnesses further contribute to the increasing demand for these drugs.

Favourable regulatory policies for approval of biosimilars

Regulatory agencies around the world have recognized the importance of establishing clear and transparent pathways for the approval of biosimilars, ensuring that these products meet stringent standards of quality, safety, and efficacy.

One of the key elements of favourable regulatory policies is the establishment of specific guidelines and frameworks tailored to the unique characteristics of biosimilars. Unlike small molecule drugs, which can be replicated with relative ease, biologics are large, complex molecules produced in living cells, making their development and characterization more challenging. Regulatory pathways allow biosimilar manufacturers to rely on existing clinical data for reference biologics, expediting the approval process while still requiring robust comparative analytical and clinical studies to demonstrate similarity and safety. By providing clear expectations and requirements, these guidelines enable manufacturers to navigate the regulatory process more efficiently and effectively, accelerating the development and approval of biosimilars.

Moreover, favourable regulatory policies include provisions to expedite the review and approval of biosimilar products, fostering competition and expanding patient access to affordable treatments. Regulatory agencies may employ mechanisms such as abbreviated pathways or priority review designations to streamline the approval process for biosimilars, particularly for products targeting diseases with significant unmet medical needs. These expedited pathways help bring biosimilar products to market more quickly, encouraging innovation and investment in the biosimilars space.

What Questions Should You Ask before Buying a Market Research Report?

How is the Biosimilars and Follow-on Biologics Market evolving?

What is driving and restraining the Biosimilars and Follow-on Biologics Market?

How will each Biosimilars and Follow-on Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Biosimilars and Follow-on Biologics submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Biosimilars and Follow-on Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Biosimilars and Follow-on Biologics projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Biosimilars and

Follow-on Biologics projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Biosimilars and Follow-on Biologics Market?

Where is the Biosimilars and Follow-on Biologics Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biosimilars and Follow-on Biologics market today, and over the next 10 years:

Our 391-page report provides 156 tables and 200 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Biosimilars and Follow-on Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Biosimilars and Follow-on Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Product Type

Recombinant Non-Glycosylated Proteins

Human Growth Hormone

Granulocyte Colony-Stimulating Factor (Filgrastim)

Insulin

Interferon

Recombinant Glycosylated Proteins

Erythropoietin

Monoclonal Antibodies (Infliximab, Rituximab, Adalimumab, Trastuzumab, Bevacizumab, Etanercept)

Follitropin

Low Molecular Weight Heparin

Application

Hematology

Neutropenia

Anemia

Others

Oncology

Lung Cancer

Brain Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Leukemia

Others

Autoimmune Disease

Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Others)

Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Diseases, Others)

Psoriasis

Others

Growth Hormone Deficiency

Diabetes

Others

Technology

Recombinant DNA (rDNA) Technology

Monoclonal Antibodies (MAb) Technology

Manufacturer

Contract Research and Manufacturing Services

In-house

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Biosimilars and Follow-on Biologics Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Amgen Inc.

Apotex (Apobiologix)

Biocad

Biocon Biologics Ltd.

Bio-Thera Solutions

Coherus Biosciences

Dr. Reddy's Laboratories

Fresenius Kabi (Fresenius SE & Co. KGaA)

Intas Pharma

Pfizer

Reliance Life Sciences

Samsung Bioepis (Samsung Biologics)

Sandoz Group AG

Teva Pharmaceuticals Industries Ltd.

Overall world revenue for Biosimilars and Follow-on Biologics Market, 2024 to 2034 in terms of value the market will surpass US$33,000 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilars and Follow-on Biologics Market, 2024 to 2034 report help you?

In summary, our 390+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Biosimilars and Follow-on Biologics Market, 2024 to 2034, with forecasts for product type, application, technology and manufacturer each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 28 key national markets - See forecasts for the Biosimilars and Follow-on Biologics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Argentina, Germany, France, UK, Spain, Italy, Russia, Poland, Belgium, China, India, Japan, Australia, South Korea, Singapore, Taiwan, GCC, and South Africa among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Biosimilars and Follow-on Biologics Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Biosimilars and Follow-On Biologics Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Expiration of Patents for Original Biologics in the recent years
      • 3.2.1.2 Increasing Incidence of Chronic Diseases
      • 3.2.1.3 Established Clear Guidelines for the Approval of Biosimilars
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 High Development Costs of follow-on biologics
      • 3.2.2.2 Lack of Interchangeability Between Biosimilars and Their Reference Biologics
      • 3.2.2.3 Intellectual Property Issues and Other Legal Challenges
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Development of Biosimilar Versions of Monoclonal Antibodies
      • 3.2.3.2 Growing Demand for Affordable Biologics in Emerging Markets
      • 3.2.3.3 Expanding the Portfolio of Biosimilars for Rare Diseases
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Biosimilars Revenue by Region
    • 3.4.1 Worldwide
    • 3.4.2 United States
    • 3.4.3 Japan
  • 3.5 Biosimilars Latest Expected Approvals
    • 3.5.1 United States
    • 3.5.2 Europe
  • 3.6 Latest Biosimilar Product Deals
  • 3.7 List of Approved Biosimilars
  • 3.8 List of Recently Launched Biosimilars
  • 3.9 Porter's Five Forces Analysis
    • 3.9.1 Bargaining Power of Suppliers
    • 3.9.2 Bargaining Power of Buyers
    • 3.9.3 Competitive Rivalry
    • 3.9.4 Threat of Substitutes
    • 3.9.5 Threat of New Entrants
  • 3.10 PEST Analysis

4 Biosimilars and Follow-On Biologics Market Analysis by Product Type

  • 4.1 Key Findings
  • 4.2 Product Type Segment: Market Attractiveness Index
  • 4.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 4.4 Recombinant Non-Glycosylated Proteins
    • 4.4.1 Recombinant Non-Glycosylated Proteins Market by Product Type
    • 4.4.2 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.3 Market Share by Region, 2024 & 2034 (%)
    • 4.4.4 Human Growth Hormone
      • 4.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.5 Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.6 Insulin
      • 4.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.6.2 Market Share by Region, 2024 & 2034 (%)
    • 4.4.7 Interferon
      • 4.4.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Recombinant Glycosylated Proteins
    • 4.5.1 Recombinant Glycosylated Proteins Market by Product Type
    • 4.5.2 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.3 Market Share by Region, 2024 & 2034 (%)
    • 4.5.4 Erythropoietin
      • 4.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.4.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.5 Monoclonal Antibodies
      • 4.5.5.1 Market Size by Monoclonal Antibodies, 2024-2034 (US$ Million)
      • 4.5.5.2 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.5.3 Market Share by Region, 2024 & 2034 (%)
    • 4.5.6 Follitropin
      • 4.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.6.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.7 Low Molecular Weight Heparin
      • 4.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 4.5.7.2 Market Share by Region, 2024 & 2034 (%)

5 Biosimilars and Follow-On Biologics Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Product Type Segment: Market Attractiveness Index
  • 5.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 5.4 Hematology
    • 5.4.1 Hematology Market Forecast by Type
    • 5.4.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.3 Market Share by Region, 2024 & 2034 (%)
    • 5.4.4 Neutropenia
      • 5.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.5 Anemia
      • 5.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.6 Others
      • 5.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Oncology
    • 5.5.1 Oncology Market Forecast by Type
    • 5.5.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.3 Market Share by Region, 2024 & 2034 (%)
    • 5.5.4 Lung Cancer
      • 5.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.4.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.5 Brain Cancer
      • 5.5.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.5.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.6 Breast Cancer
      • 5.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.6.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.7 Cervical Cancer
      • 5.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.7.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.8 Colorectal Cancer
      • 5.5.8.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.8.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.9 Leukemia
      • 5.5.9.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.9.2 Market Share by Region, 2024 & 2034 (%)
    • 5.5.10 Others
      • 5.5.10.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Autoimmune Disease
    • 5.6.1 Autoimmune Disease Market Forecast by Type
    • 5.6.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.4 Arthritis
      • 5.6.4.1 Market Size by Type, 2024-2034 (US$ Million)
      • 5.6.4.2 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.4.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.5 Inflammatory Bowel Disease
      • 5.6.5.1 Market Size by Type, 2024-2034 (US$ Million)
      • 5.6.5.2 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.5.3 Market Share by Region, 2024 & 2034 (%)
    • 5.6.6 Psoriasis
      • 5.6.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.6.2 Market Share by Region, 2024 & 2034 (%)
    • 5.6.7 Others
      • 5.6.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Growth Hormone Deficiency
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Diabetes
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Biosimilars and Follow-On Biologics Market Analysis by Technology

  • 6.1 Key Findings
  • 6.2 Technology Segment: Market Attractiveness Index
  • 6.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Technology
  • 6.4 Recombinant DNA (rDNA) Technology
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Monoclonal Antibodies (MAb) Technology
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Biosimilars and Follow-On Biologics Market Analysis by Manufacturer

  • 7.1 Key Findings
  • 7.2 Product Type Segment: Market Attractiveness Index
  • 7.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 7.4 Contract Research and Manufacturing Services
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 In-house
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 Biosimilars and Follow-On Biologics Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Biosimilars and Follow-On Biologics Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 9.3 North America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 9.5 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 9.6 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 9.7 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 9.8 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 9.9 U.S. Biosimilars and Follow-On Biologics Market Analysis
  • 9.10 Canada Biosimilars and Follow-On Biologics Market Analysis

10 Europe Biosimilars and Follow-On Biologics Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 10.3 Europe Biosimilars and follow-on biologics market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 10.5 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 10.6 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 10.7 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 10.8 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 10.9 Germany Biosimilars and Follow-On Biologics Market Analysis
  • 10.10 France Biosimilars and Follow-On Biologics Market Analysis
  • 10.11 UK Biosimilars and Follow-On Biologics Market Analysis
  • 10.12 Italy Biosimilars and Follow-On Biologics Market Analysis
  • 10.13 Spain Biosimilars and Follow-On Biologics Market Analysis
  • 10.14 Russia Biosimilars and Follow-On Biologics Market Analysis
  • 10.15 Poland Biosimilars and Follow-On Biologics Market Analysis
  • 10.16 Belgium Biosimilars and Follow-On Biologics Market Analysis
  • 10.17 Rest of Europe Biosimilars and Follow-On Biologics Market Analysis

11 Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 11.3 Asia Pacific Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 11.6 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 11.7 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 11.8 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 11.9 Japan Biosimilars and Follow-On Biologics Market Analysis
  • 11.10 China Biosimilars and Follow-On Biologics Market Analysis
  • 11.11 India Biosimilars and Follow-On Biologics Market Analysis
  • 11.12 Australia Biosimilars and Follow-On Biologics Market Analysis
  • 11.13 South Korea Biosimilars and Follow-On Biologics Market Analysis
  • 11.14 Singapore Biosimilars and Follow-On Biologics Market Analysis
  • 11.15 Taiwan Biosimilars and Follow-On Biologics Market Analysis
  • 11.16 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

12 Latin America Biosimilars and Follow-On Biologics Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 12.3 Latin America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 12.5 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 12.6 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 12.7 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 12.8 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 12.9 Brazil Biosimilars and Follow-On Biologics Market Analysis
  • 12.10 Mexico Biosimilars and Follow-On Biologics Market Analysis
  • 12.11 Argentina Biosimilars and Follow-On Biologics Market Analysis
  • 12.12 Colombia Biosimilars and Follow-On Biologics Market Analysis
  • 12.13 Rest of Latin America Biosimilars and Follow-On Biologics Market Analysis

13 MEA Biosimilars and Follow-On Biologics Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
  • 13.3 MEA Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
  • 13.5 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
  • 13.6 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
  • 13.7 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
  • 13.8 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
  • 13.9 GCC Biosimilars and Follow-On Biologics Market Analysis
  • 13.10 South Africa Biosimilars and Follow-On Biologics Market Analysis
  • 13.11 Rest of MEA Biosimilars and Follow-On Biologics Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Amgen Inc.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2023
      • 14.3.3.2 R&D, 2017-2023
      • 14.3.3.3 Regional Market Shares, 2023
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Apotex (Apobiologix)
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Product Benchmarking
    • 14.4.4 Strategic Outlook
  • 14.5 Biocad
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 Biocon Biologics Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2017-2023
      • 14.6.3.2 Regional Market Shares, 2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Bio-Thera Solutions
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 Coherus Biosciences
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2019-2023
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Dr. Reddy's Laboratories
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Fresenius Kabi (Fresenius SE & Co. KGaA)
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2019-2023
      • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Intas Pharma
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Strategic Outlook
  • 14.12 Pfizer
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2023
      • 14.12.3.2 R&D, 2017-2023
      • 14.12.3.3 Regional Market Shares, 2023
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Reliance Life Sciences
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
    • 14.13.4 Strategic Outlook
  • 14.14 Samsung Bioepis (Samsung Biologics)
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Sandoz Group AG
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2022-2023
      • 14.15.3.2 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Teva Pharmaceuticals Industries Ltd.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2023
      • 14.16.3.2 R&D, 2017-2023
      • 14.16.3.3 Regional Market Shares, 2023
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Biosimilars and Follow-On Biologics Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Cost comparison of a Biosimilars and their reference products
  • Table 3 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7 Worldwide Biosimilars Revenue 2023 (US$ Million)
  • Table 8 United States Biosimilars Revenue 2023 (US$ Million)
  • Table 9 Japan Biosimilars Revenue 2023 (US$ Million)
  • Table 10 United States Biosimilars Latest Expected Approvals
  • Table 11 Europe Biosimilars Latest Expected Approvals
  • Table 12 Europe Biosimilars Latest Expected Approvals
  • Table 13 List of Approved Biosimilars
  • Table 14 List of Recently Launched Biosimilars
  • Table 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 16 Recombinant Non-Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 18 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 19 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 20 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 21 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 22 Recombinant Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 23 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 25 Recombinant Glycosylated Proteins Segment Market Forecast by Monoclonal Antibodies, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 26 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 28 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 29 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 30 Hematology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 31 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 32 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 33 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 Oncology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 36 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 37 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 38 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 39 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 40 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 41 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 42 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 43 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 Autoimmune Disease Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 45 Autoimmune Disease Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Autoimmune Disease Segment Market Forecast by Arthritis, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 47 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 48 Autoimmune Disease Segment Market Forecast by Inflammatory Bowel Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 50 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 51 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 52 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 54 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 55 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 56 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 57 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 59 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 62 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 63 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 64 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 65 North America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 66 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 67 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 69 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 71 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 72 Europe Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 73 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 74 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 75 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 76 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 77 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 78 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 79 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 80 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 81 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 82 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 83 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 84 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 85 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 86 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 87 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 88 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 89 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 90 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 91 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 92 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 93 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 94 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 95 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 96 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 97 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 98 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 99 Latin America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 100 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 101 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 102 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 103 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 104 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 105 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 106 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 107 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 108 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 109 MEA Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 110 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 111 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 112 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 113 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 114 Strategic Outlook
  • Table 115 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Amgen Inc.: Product Benchmarking
  • Table 117 Amgen Inc.: Strategic Outlook
  • Table 118 Apotex (Apobiologix): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Apotex (Apobiologix): Product Benchmarking
  • Table 120 Apotex (Apobiologix): Strategic Outlook
  • Table 121 Biocad: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Biocad: Product Benchmarking
  • Table 123 Biocad: Strategic Outlook
  • Table 124 Biocon Biologics Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 Biocon Biologics Ltd.: Product Benchmarking
  • Table 126 Biocon Biologics Ltd.: Strategic Outlook
  • Table 127 Bio-Thera Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Bio-Thera Solutions: Product Benchmarking
  • Table 129 Bio-Thera Solutions: Strategic Outlook
  • Table 130 Coherus Biosciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Coherus Biosciences: Product Benchmarking
  • Table 132 Coherus Biosciences: Strategic Outlook
  • Table 133 Dr. Reddy's Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 Dr. Reddy's Laboratories: Product Benchmarking
  • Table 135 Dr. Reddy's Laboratories: Strategic Outlook
  • Table 136 Fresenius Kabi (Fresenius SE & Co. KGaA): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Fresenius Kabi (Fresenius SE & Co. KGaA): Product Benchmarking
  • Table 138 Fresenius Kabi (Fresenius SE & Co. KGaA): Strategic Outlook
  • Table 139 Intas Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 Intas Pharma: Product Benchmarking
  • Table 141 Intas Pharma: Strategic Outlook
  • Table 142 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Pfizer: Product Benchmarking
  • Table 144 Pfizer: Strategic Outlook
  • Table 145 Reliance Life Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Reliance Life Sciences: Product Benchmarking
  • Table 147 Reliance Life Sciences: Strategic Outlook
  • Table 148 Samsung Bioepis (Samsung Biologics): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Samsung Bioepis (Samsung Biologics): Product Benchmarking
  • Table 150 Samsung Bioepis (Samsung Biologics): Strategic Outlook
  • Table 151 Sandoz Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 152 Sandoz Group AG: Product Benchmarking
  • Table 153 Sandoz Group AG: Strategic Outlook
  • Table 154 Teva Pharmaceuticals Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 Teva Pharmaceuticals Industries Ltd.: Product Benchmarking
  • Table 156 Teva Pharmaceuticals Industries Ltd.: Strategic Outlook

List of Figures

  • Figure 1 Biosimilars and Follow-On Biologics Market Segmentation
  • Figure 2 Biosimilars and Follow-On Biologics Market by Product Type: Market Attractiveness Index
  • Figure 3 Biosimilars and Follow-On Biologics Market Application: Market Attractiveness Index
  • Figure 4 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
  • Figure 5 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
  • Figure 6 Biosimilars and Follow-On Biologics Market Attractiveness Index by Region
  • Figure 7 Biosimilars and Follow-On Biologics Market: Market Dynamics
  • Figure 8 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 9 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 10 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 11 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 12 Biosimilars and Follow-On Biologics Market: Porter's Five Forces Analysis
  • Figure 13 Biosimilars and Follow-On Biologics Market: PEST Analysis
  • Figure 14 Biosimilars and Follow-On Biologics Market by Product type: Market Attractiveness Index
  • Figure 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 16 Biosimilars and Follow-On Biologics Market Share Forecast by Product type, 2024, 2029, 2034 (%)
  • Figure 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 18 Recombinant Non-Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 20 Human Growth Hormone Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 22 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 24 Insulin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 26 Interferon Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 28 Recombinant Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 30 Erythropoietin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 32 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Follitropin Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Low Molecular Weight Heparin Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Biosimilars and Follow-On Biologics Market by Application: Market Attractiveness Index
  • Figure 38 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 39 Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 40 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 41 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Neutropenia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 44 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Anemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 51 Lung Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 53 Brain Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 55 Breast Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 57 Cervical Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 59 Colorectal Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 60 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 61 Leukemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 62 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 63 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 64 Autoimmune Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 65 Autoimmune Disease Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 66 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 67 Arthritis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 68 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 69 Inflammatory Bowel Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 70 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 71 Psoriasis Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 74 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Growth Hormone Deficiency Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 76 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 77 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 78 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 79 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 80 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
  • Figure 81 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 82 Biosimilars and Follow-On Biologics Market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 83 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Recombinant DNA (rDNA) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 85 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 86 Monoclonal Antibodies (MAb) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 87 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
  • Figure 88 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 89 Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024, 2029, 2034 (%)
  • Figure 90 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Contract Research and Manufacturing Services Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 92 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 93 In-house Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 94 Biosimilars and Follow-On Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 95 Biosimilars and Follow-On Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 96 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 97 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 98 North America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 99 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 100 North America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 101 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 102 North America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 103 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 104 North America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 105 North America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 106 North America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 107 North America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 108 North America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 109 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 112 Europe Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 113 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 115 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 117 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 118 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 119 Europe Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Europe Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 121 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 123 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 124 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 125 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 133 Asia Pacific Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 134 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 135 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 136 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 137 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 138 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 139 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 140 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 141 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 142 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 143 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 144 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 145 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 146 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 149 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 150 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 151 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 152 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 153 Latin America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 154 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 155 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 156 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 157 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 158 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 159 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 160 Latin America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 161 Latin America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 162 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 163 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 164 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 165 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 166 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 167 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 168 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 169 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
  • Figure 170 MEA Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 171 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 172 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 173 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
  • Figure 174 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
  • Figure 175 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
  • Figure 176 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 177 MEA Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
  • Figure 178 MEA Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
  • Figure 179 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
  • Figure 180 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
  • Figure 181 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 182 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 183 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 184 Biosimilars and Follow-On Biologics Market: Company Share
  • Figure 185 Amgen Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 186 Amgen Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 187 Amgen Inc.: Regional Market Shares, 2023
  • Figure 188 Biocon Biologics Ltd.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 189 Biocon Biologics Ltd.: Regional Market Shares, 2023
  • Figure 190 Coherus Biosciences: Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 191 Fresenius Kabi (Fresenius SE & Co. KGaA): Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 192 Fresenius Kabi (Fresenius SE & Co. KGaA): Regional Market Shares, 2023
  • Figure 193 Pfizer: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 194 Pfizer R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 195 Pfizer Regional Market Shares, 2023
  • Figure 196 Sandoz Group AG: Net Revenue, 2022-2023 (US$ Million, AGR%)
  • Figure 197 Sandoz Group AG: Regional Market Shares, 2023
  • Figure 198 Teva Pharmaceuticals Industries Ltd: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 199 Teva Pharmaceuticals Industries Ltd: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 200 Teva Pharmaceuticals Industries Ltd: Regional Market Shares, 2023